Previous 10 | Next 10 |
Advaxis (NASDAQ: ADXS ) and Personalis (NASDAQ: PSNL ) have collaborated to leverage Personalis’ ImmunoID NeXT Platform in Advaxis’ ongoing Phase 1/2 ADXS-503 (HOT Lung) program evaluating ADXS-503 alone and in combination with pembrolizumab in patients with non-small cell lu...
PRINCETON, N.J. and MENLO PARK, Calif., Feb. 11, 2020 (GLOBE NEWSWIRE) -- Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, and Personalis Inc. (Nasdaq: PSNL), a leader in advanced genomics for ca...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the Precision Medicine World Conference (PMWC) 2020 in Santa Clara, CA January 22-24. The presentation titled “Enabling Advanced Composite Biomarkers for ...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced the launch of the NeXT Dx™ Test to help oncologists identify potential therapies and clinical trial options for cancer patients. The Personalis NeXT Dx™ Test is one of the first cancer dia...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will participate in the ESMO Immuno-Oncology Congress 2019 in Geneva, Switzerland, December 11-14, including a poster presentation on December 12 th . The poster presentation , tit...
Are small-cap stocks poised for a breakout? That's what some analysts and hedge fund managers are arguing. The idea is that passive investing, or tossing a bunch of money into an index fund and forgetting about it because you have better stuff to do, is driving a wedge between small compa...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that the company will present at the NeoAg Summit US 2019 in Boston on November 21 st at 9:15 AM EST. The presentation , entitled “ImmunoID NeXT: A Comprehensive Platform for Improving Neoa...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, today announced that Aaron Tachibana, Chief Financial Officer and Clinton Musil, Chief Business Officer, are scheduled to present at the following upcoming investor conferences. Piper Jaffray 31 st Annual Health...
SAExploration Holdings (NASDAQ: SAEX ) +183% on $130M of new projects in Alaska, Canada and the Middle East. More news on: SAExploration Holdings, Inc., Myovant Sciences Ltd., The Medicines Company, Stocks on the move, Read more ...
Personalis, Inc. (Nasdaq:PSNL), a leader in advanced genomics for cancer, today announced a collaboration with Merck KGaA, Darmstadt, Germany, a leading science and technology company, to investigate novel biomarkers of response and mechanisms of resistance to cancer therapies. Merck KGaA, Da...
News, Short Squeeze, Breakout and More Instantly...
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its second quarter 2024 financial results on Wednesday, August 7, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific...
A look at the top 10 most actives in the United States Serve Robotics Inc. (SERV) rose 187.1% to $7.55 on volume of 255,453,115 shares 60 Degrees Pharmaceuticals Inc. (SXTP) rose 10.2% to $0.271 on volume of 224,640,171 shares NVIDIA Corporation (NVDA) fell 2.6% to $117.93 on volume of 21...
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL) today announced that they have entered into an agreement to cross-license patent estates covering tum...